Home › Companies › Esperion Therapeutics, Inc. › 2025-2026

Esperion Therapeutics, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Esperion Therapeutics, Inc.’s Form 8-K, filed 2026-06-01 (Item 5.07 on EDGAR). Page generated 02 October 2026.

9Reported items
164Asset managers
916Fund votes
2026-05-28Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Esperion Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Esperion Therapeutics, Inc.

These tallies are Esperion Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-01 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Esperion Therapeutics, Inc. — official shareholder meeting results, meeting held 2026-05-28
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: J. Martin Carroll	105,082,565	--	--	26,011,489	46,114,802	Majority: yes
Elect Director: Sheldon L. Koenig	109,672,941	--	--	21,421,113	46,114,802	Majority: yes
The Company's stockholders approved Proposal 2.	95,650,226	34,866,033	577,795	--	46,114,802	Majority: yes
The Company's stockholders approved Proposal 3.	167,083,447	8,765,273	1,360,136	--	--	Majority: yes
The Company's stockholders approved Proposal 4.	108,150,213	22,489,001	454,840	--	46,114,802	Majority: yes

Source: Esperion Therapeutics, Inc., Form 8-K, filed with the SEC on 2026-06-01 — read the filing on EDGAR.

How asset managers voted at the Esperion Therapeutics, Inc. 2025-2026 meeting

Each item below shows how the 164 asset managers that disclosed a Esperion Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Esperion Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve the non-binding advisory resolution on the compensation of our named executive officers.

SECTION 14A SAY-ON-PAY VOTES

Combines 2 wordings of this item as funds reported it.

89% fund support · no official result

FOR 89%11%

The 159 asset managers below cast 89% of the shares they voted on this item FOR (102,949,547 for, 13,154,135 against).

FOR: 102,949,547 (88.7%)AGAINST: 13,154,135 (11.3%)ABSTAIN: 3 (0.0%)

Largest asset managers voting on “To approve the non-binding advisory resolution on the compensation of our named executive officers.” at Esperion Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
BlackRock	13,984,210	32,341	0	For
Vanguard	13,793,997	9,918	3	For
WASATCH ADVISORS LP	12,205,875	151,241	0	For
WASATCH FUNDS TRUST	10,839,106	0	0	For
ORBIMED ADVISORS LLC	0	6,645,349	0	Against
GEODE CAPITAL MANAGEMENT, LLC	5,955,739	0	0	For
Fidelity	5,732,081	0	0	For
State Street	5,587,793	8,438	0	For
Two Seas Capital LP	5,488,185	0	0	For
PenderFund Capital Management Ltd.	3,558,688	0	0	For
Nuveen	2,829,678	0	0	For
MARSHALL WACE, LLP	0	2,760,045	0	Against
TIAA	2,753,686	0	0	For
Royce	2,626,995	0	0	For
Two Sigma	2,193,045	0	0	For
Edward D. Jones & Co., L.P.	2,135,668	0	0	For
Utah Retirement Systems	2,062,592	0	0	For
Northern Trust	1,881,920	0	0	For
Charles Schwab	1,340,458	0	0	For
Renaissance	755,661	0	0	For
MELLON INVESTMENTS Corp	0	739,487	0	Against
MACKENZIE FINANCIAL CORP	0	659,120	0	Against
Lazard	0	580,705	0	Against
Equitable	566,779	0	0	For
PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO	532,449	0	0	For

Showing the 25 largest of 159 asset managers. See all 159 in the interactive database.

2. Election of Class I Directors: J. Martin Carroll

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

80% Majority: yes · of votes cast

FOR 80%WITHHELD 20%

FOR: 105,082,565WITHHELD: 26,011,489

Esperion Therapeutics, Inc.’s own tally for this item (“Elect Director: J. Martin Carroll”): 105,082,565 for, 26,011,489 withheld, per its Form 8-K filed 2026-06-01 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 257,431,942 outstanding shares: 41% for, 10% withheld (50.9% of the company cast a for/withheld vote).

The 47 asset managers below cast 100% of the shares they voted on this item FOR (44,988,169 for, 0 against).

FOR 93%7%

FOR: 44,988,169 (92.9%)ABSTAIN: 3,455,710 (7.1%)

Largest asset managers voting on “Election of Class I Directors: J. Martin Carroll” at Esperion Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	12,053,055	30,564	For
WASATCH FUNDS TRUST	10,839,106	0	For
BlackRock	8,220,443	0	For
Fidelity	5,407,865	0	For
TIAA	0	2,753,686	Abstain
Royce	2,602,488	0	For
State Street	2,282,910	1,207	For
Charles Schwab	670,173	0	For
Equitable	386,049	180,730	For
Principal Exchange-Traded Funds	409,645	0	For
QUANTITATIVE MASTER SERIES LLC	382,198	0	For
Lincoln Financial	248,556	0	For
Goldman Sachs	0	223,679	Abstain
ETFis Series Trust I	219,293	0	For
Eleva Capital SAS	183,047	0	For
ProShares	136,503	0	For
Invesco	114,015	0	For
Global X	112,469	0	For
Northern Trust	0	111,033	Abstain
AIG/SunAmerica	102,310	0	For
Bridge Builder Trust	83,617	0	For
John Hancock	64,309	0	For
Brighthouse	58,177	0	For
Direxion Shares ETF Trust	54,545	0	For
Blackstone Alternative Investment Funds	52,400	0	For

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

3. Election of Class I Directors: Sheldon L. Koenig

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

84% Majority: yes · of votes cast

FOR 84%WITHHELD 16%

FOR: 109,672,941WITHHELD: 21,421,113

Esperion Therapeutics, Inc.’s own tally for this item (“Elect Director: Sheldon L. Koenig”): 109,672,941 for, 21,421,113 withheld, per its Form 8-K filed 2026-06-01 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 257,431,942 outstanding shares: 43% for, 8% withheld (50.9% of the company cast a for/withheld vote).

The 47 asset managers below cast 100% of the shares they voted on this item FOR (48,380,214 for, 0 against).

FOR 99.8%

FOR: 48,380,214 (99.9%)ABSTAIN: 63,665 (0.1%)

Largest asset managers voting on “Election of Class I Directors: Sheldon L. Koenig” at Esperion Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	12,062,864	20,755	For
WASATCH FUNDS TRUST	10,839,106	0	For
BlackRock	8,220,443	0	For
Fidelity	5,407,865	0	For
TIAA	2,753,686	0	For
Royce	2,602,488	0	For
State Street	2,282,910	1,207	For
Charles Schwab	670,173	0	For
Equitable	566,779	0	For
Principal Exchange-Traded Funds	409,645	0	For
QUANTITATIVE MASTER SERIES LLC	382,198	0	For
Lincoln Financial	248,556	0	For
Goldman Sachs	223,679	0	For
ETFis Series Trust I	219,293	0	For
Eleva Capital SAS	183,047	0	For
ProShares	136,503	0	For
Invesco	114,015	0	For
Global X	112,469	0	For
Northern Trust	111,033	0	For
AIG/SunAmerica	102,310	0	For
Bridge Builder Trust	83,617	0	For
John Hancock	64,309	0	For
Brighthouse	58,177	0	For
Direxion Shares ETF Trust	54,545	0	For
Blackstone Alternative Investment Funds	52,400	0	For

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

4. TO APPROVE AN AMENDMENT TO THE ESPERION THERAPEUTICS, INC. 2022 STOCK OPTION AND INCENTIVE PLAN.

COMPENSATION

99.8% fund support · no official result

FOR 99.8%

The 45 asset managers below cast 99.8% of the shares they voted on this item FOR (48,196,741 for, 64,042 against).

FOR: 48,196,741 (99.9%)AGAINST: 64,042 (0.1%)ABSTAIN: 1 (0.0%)

Largest asset managers voting on “TO APPROVE AN AMENDMENT TO THE ESPERION THERAPEUTICS, INC. 2022 STOCK OPTION AND INCENTIVE PLAN.” at Esperion Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	12,062,858	20,759	1	For
WASATCH FUNDS TRUST	10,839,106	0	0	For
BlackRock	8,220,443	0	0	For
Fidelity	5,407,865	0	0	For
TIAA	2,753,686	0	0	For
Royce	2,602,488	0	0	For
State Street	2,282,537	1,580	0	For
Charles Schwab	670,173	0	0	For
Equitable	566,779	0	0	For
Principal Exchange-Traded Funds	409,645	0	0	For
QUANTITATIVE MASTER SERIES LLC	382,198	0	0	For
Lincoln Financial	248,556	0	0	For
Goldman Sachs	223,679	0	0	For
ETFis Series Trust I	219,293	0	0	For
ProShares	136,503	0	0	For
Invesco	114,015	0	0	For
Global X	112,469	0	0	For
Northern Trust	111,033	0	0	For
AIG/SunAmerica	102,310	0	0	For
Bridge Builder Trust	83,617	0	0	For
John Hancock	64,309	0	0	For
Brighthouse	58,177	0	0	For
Direxion Shares ETF Trust	54,545	0	0	For
Blackstone Alternative Investment Funds	52,400	0	0	For
Jacob Funds Inc.	470	40,430	0	Against

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

5. TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

AUDIT-RELATED

99.9% fund support · no official result

FOR 99.9%

The 45 asset managers below cast 99.9% of the shares they voted on this item FOR (48,260,392 for, 389 against).

FOR: 48,260,392 (100.0%)AGAINST: 389 (0.0%)ABSTAIN: 4 (0.0%)

Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FI” at Esperion Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	12,083,599	16	4	For
WASATCH FUNDS TRUST	10,839,106	0	0	For
BlackRock	8,220,443	0	0	For
Fidelity	5,407,865	0	0	For
TIAA	2,753,686	0	0	For
Royce	2,602,488	0	0	For
State Street	2,283,744	373	0	For
Charles Schwab	670,173	0	0	For
Equitable	566,779	0	0	For
Principal Exchange-Traded Funds	409,645	0	0	For
QUANTITATIVE MASTER SERIES LLC	382,198	0	0	For
Lincoln Financial	248,556	0	0	For
Goldman Sachs	223,679	0	0	For
ETFis Series Trust I	219,293	0	0	For
ProShares	136,503	0	0	For
Invesco	114,015	0	0	For
Global X	112,469	0	0	For
Northern Trust	111,033	0	0	For
AIG/SunAmerica	102,310	0	0	For
Bridge Builder Trust	83,617	0	0	For
John Hancock	64,309	0	0	For
Brighthouse	58,177	0	0	For
Direxion Shares ETF Trust	54,545	0	0	For
Blackstone Alternative Investment Funds	52,400	0	0	For
Jacob Funds Inc.	40,900	0	0	For

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

6. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 100%

The 3 asset managers below cast 100% of the shares they voted on this item FOR (643,727 for, 0 against).

FOR: 643,727 (100.0%)

Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at Esperion Therapeutics, Inc., 2025-2026
Asset manager	For	Vote
Eversept Partners, LP	460,633	For
Eleva Capital SAS	183,047	For
CLEARWATER INVESTMENT TRUST	47	For

7. Amend Omnibus Stock Plan

COMPENSATION

100% fund support · no official result

FOR 100%

The 3 asset managers below cast 100% of the shares they voted on this item FOR (643,727 for, 0 against).

FOR: 643,727 (100.0%)

Largest asset managers voting on “Amend Omnibus Stock Plan” at Esperion Therapeutics, Inc., 2025-2026
Asset manager	For	Vote
Eversept Partners, LP	460,633	For
Eleva Capital SAS	183,047	For
CLEARWATER INVESTMENT TRUST	47	For

8. 14A Executive Compensation

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 99.9%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (2,914,274 for, 0 against).

FOR: 2,914,274 (100.0%)ABSTAIN: 315 (0.0%)

Largest asset managers voting on “14A Executive Compensation” at Esperion Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
AIGH Capital Management LLC	2,914,274	0	0	0	For
LEAVELL INVESTMENT MANAGEMENT, INC.	0	0	315	0	Abstain

9. Ratify Ernst & Young LLP as Auditors

AUDIT-RELATED

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (183,094 for, 0 against).

FOR: 183,094 (100.0%)

Largest asset managers voting on “Ratify Ernst & Young LLP as Auditors” at Esperion Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
Eleva Capital SAS	183,047	0	0	0	For
CLEARWATER INVESTMENT TRUST	47	0	0	0	For

Largest Esperion Therapeutics, Inc. shareholders voting in 2025-2026

Ranked by the number of Esperion Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 257,431,942 shares outstanding at the time of that meeting.

Top Esperion Therapeutics, Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	BlackRock	5.44%
2	Vanguard	5.36%
3	WASATCH ADVISORS LP	4.80%
4	WASATCH FUNDS TRUST	4.21%
5	ORBIMED ADVISORS LLC	2.58%
6	GEODE CAPITAL MANAGEMENT, LLC	2.31%
7	Fidelity	2.23%
8	State Street	2.17%
9	Two Seas Capital LP	2.13%
10	PenderFund Capital Management Ltd.	1.38%

Reported Esperion Therapeutics, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Esperion Therapeutics, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
Glazer Capital, LLC	8.15%	13G
BlackRock	6.93%	13F
Vanguard Group	5.81%	13F
Two Sigma	3.67%	13F
State Street	2.74%	13F
D.E. Shaw	2.54%	13F
Morgan Stanley	1.37%	13F
Goldman Sachs	0.94%	13F
Northern Trust	0.82%	13F
Wasatch Advisors LP	0.75%	13G

Percentages above are of 257,431,942 shares outstanding, as reported by Esperion Therapeutics, Inc. on its Form 10-Q dated 2026-04-30 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Esperion Therapeutics, Inc.’s 10-Q dated 2026-04-30. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Esperion Therapeutics, Inc.'s shareholder meeting held 2026-05-28, in the 2025-2026 proxy season, 164 asset managers reported how they voted in their SEC Form N-PX filings, covering 916 separate fund positions. Their filings are grouped here into 9 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. Esperion Therapeutics, Inc.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To approve the non-binding advisory resolution on the compensation of our named executive… — the reporting funds cast 89% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

Esperion Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).